SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VBIO

Valion Bio, Inc. (NASDAQ:VBIO)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.48-$0.06 (-10.98%)
 
Market cap
$1.04M
Insider Score
Health Score
Listed since
Nov 11, 2021
Market Cap$1.04M-98.8%
Revenue (ttm)-$156.00K-139.8%
Net Income-$18.75M-195.7%
EPS-$8.70-49.9%
Shares Out2.16M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume135,203
Open$0.54
Previous Close$0.54
Day's Range$0.48 - $0.55
52-Week Range$0.47 - $67.50
Beta1.91
Analystsn/a
Price Targetn/a
Earnings DateNov 23, 2026
-11.09% (1D)
No price history available.

About VBIO

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Address
1305 E. Houston Street, San Antonio, TX, 78205, US
Market Cap
1 million
Employees
52
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$28.45K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From VBIO’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-10.98%
5 Days
-10.98%
1 Month
-57.09%
6 Months
-97.81%
1 Year
-98.83%

$VBIO stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VBIO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VBIO's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VBIO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

VBIO Revenue by Segment

$21.32MTotal
Property and equipment, net$12.34M57.90%
Goodwill$3.46M16.22%
Licensed technology, net$2.24M10.52%
Cash and cash equivalents$2.11M9.89%
Inventory, net$750.00K3.52%
Restricted cash$368.00K1.73%
Change in fair value of derivative liability$47.00K0.22%

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New VBIO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VBIO from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from VBIO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
0
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$28.45K
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.